Drug intelligence / Profile preview

PF-07832837

Development stage: Phase 1
Lead developer: Pfizer
Administration: Intravenous, Subcutaneous

Overview

PF-07832837 is an investigational biologic drug developed by Pfizer, currently in Phase 1 clinical trials for the treatment of atopic dermatitis and asthma. It is administered parenterally (intravenous or subcutaneous). The precise mechanism of action has not been disclosed. Early-stage studies are evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy participants and patients with moderate to severe atopic dermatitis[1][2][3][4][5][6][7][8].

Beyond the preview

Go deeper on PF-07832837.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-07832837.

Explore the full profile